UBS has reiterated its overweight stance on European pharmaceuticals, viewing the sector as a more stable investment than artificial intelligence amid a slowing market. The bank highlights improving earnings, low valuations, and lighter ownership as key positives, with weight-loss drugs like Novo Nordisk's Wegovy as a strong near-term catalyst. UBS advises careful stock selection due to upcoming patent cliffs, favoring companies like Merck KGaA, Galderma, AstraZeneca, and Roche. It remains cautious on Novartis and Sanofi and sees AI's most investable uses as practical applications rather than drug discovery.
Novo Nordisk shares dropped 2.5% after Deutsche Bank's weekly prescription data tracker indicated a continued slowdown in the oral version of its weight-loss drug, Wegovy, in the US. This slowdown is significant because the oral formulation was seen ...
The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...
Novo Nordisk is rated a BUY as its oral Wegovy drug rapidly expands the obesity treatment market in the U.S., with over 3 million prescriptions in five months, mostly from patients new to GLP-1 treatments. This strong demand has led management to rai...
